Tag: FIRST@CIRSE

rivaroxaban

Patients with multiple revascularisations are at higher risk of acute limb...

Symptomatic peripheral arterial disease (PAD) patients undergoing recurrent lower extremity revascularisation have higher rates of ischaemic events, particularly acute limb ischaemia, than those patients...
reimbursement

Calls in Germany for reimbursement as analysis shows drug-eluting technology is...

Stefan Müller-Hülsbeck (Ev Luth Diakonissenanstalt zu Flensburg, Flensburg, Germany) presented attendees of the online meeting of the Cardiovascular and Interventional Radiological Society of Europe...
Luminor

“No signal of increased risk of long-term mortality” with paclitaxel-coated Luminor...

An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two...
SAVER

Win for paclitaxel as SAVER registry “reinforces the safety profile” of...

“The SAVER registry reinforces the safety and effectiveness profile for the Stellarex drug-coated balloon (DCB; Philips) in a real-world patient population,” Konstantinos Stavroulakis (St...
covered

24-month AVeNEW study results: Covered stent angioplasty “statistically superior” to angioplasty...

Against the backdrop of increasing end-stage renal disease (ESRD) prevalence in the USA, Bart Dolmatch (Portola Valley, USA) presented the 24-month results of the...
predict

New prediction model for target lesion revascularisation grants “new level of...

“Please feel free to utilise this in your practice,” Michael Dake (University of Arizona Health Sciences, Tucson, USA) urged on the first day of...